Amicus Therapeutics, Inc. (NASDAQ:FOLD) Chairman John F. Crowley Sells 10,468 Shares

Amicus Therapeutics, Inc. (NASDAQ:FOLDGet Rating) Chairman John F. Crowley sold 10,468 shares of the business’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $10.66, for a total transaction of $111,588.88. Following the completion of the transaction, the chairman now owns 856,897 shares of the company’s stock, valued at $9,134,522.02. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Amicus Therapeutics Price Performance

Shares of FOLD opened at $10.58 on Tuesday. The firm has a market cap of $2.97 billion, a PE ratio of -10.69 and a beta of 0.91. The company has a current ratio of 3.02, a quick ratio of 2.90 and a debt-to-equity ratio of 2.25. The firm has a fifty day simple moving average of $11.29 and a two-hundred day simple moving average of $9.61. Amicus Therapeutics, Inc. has a 1-year low of $5.91 and a 1-year high of $12.96.

Amicus Therapeutics (NASDAQ:FOLDGet Rating) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. Amicus Therapeutics had a negative net margin of 87.50% and a negative return on equity of 102.55%. During the same quarter last year, the firm posted ($0.19) earnings per share. On average, equities analysts anticipate that Amicus Therapeutics, Inc. will post -0.9 EPS for the current year.

Institutional Investors Weigh In On Amicus Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Advisor Group Holdings Inc. grew its position in shares of Amicus Therapeutics by 30.4% during the 4th quarter. Advisor Group Holdings Inc. now owns 9,516 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 2,217 shares during the period. Raymond James & Associates grew its position in shares of Amicus Therapeutics by 5.6% during the 4th quarter. Raymond James & Associates now owns 27,687 shares of the biopharmaceutical company’s stock valued at $320,000 after acquiring an additional 1,459 shares during the period. Teacher Retirement System of Texas grew its position in shares of Amicus Therapeutics by 20.9% during the 4th quarter. Teacher Retirement System of Texas now owns 41,164 shares of the biopharmaceutical company’s stock valued at $475,000 after acquiring an additional 7,113 shares during the period. Citigroup Inc. grew its position in shares of Amicus Therapeutics by 62.3% during the 4th quarter. Citigroup Inc. now owns 509,286 shares of the biopharmaceutical company’s stock valued at $5,883,000 after acquiring an additional 195,405 shares during the period. Finally, Pictet Asset Management SA grew its position in shares of Amicus Therapeutics by 7.3% during the 4th quarter. Pictet Asset Management SA now owns 421,817 shares of the biopharmaceutical company’s stock valued at $4,872,000 after acquiring an additional 28,773 shares during the period.

Wall Street Analyst Weigh In

Separately, Morgan Stanley started coverage on shares of Amicus Therapeutics in a report on Friday, September 9th. They issued an “equal weight” rating and a $14.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Amicus Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

About Amicus Therapeutics

(Get Rating)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.

Featured Articles

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.